Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005-05-01
Randomized trial of hyperthermia and radiation for superficial tumors.
ABSTRACT
PURPOSE
Randomized clinical trials have demonstrated hyperthermia (HT) enhances radiation response. These trials, however, generally lacked rigorous thermal dose prescription and administration. We report the final results of a prospective randomized trial of superficial tumors (
METHODS
This trial was designed to test whether a thermal dose of more than 10 CEM 43 degrees C T(90) results in improved complete response and duration of local control compared with a thermal dose of
RESULTS
One hundred twenty-two patients were enrolled; 109 (89%) were deemed heatable and were randomly assigned. The complete response rate was 66.1% in the HT arm and 42.3% in the no-HT arm. The odds ratio for complete response was 2.7 (95% CI, 1.2 to 5.8; P = .02). Previously irradiated patients had the greatest incremental gain in complete response: 23.5% in the no-HT arm versus 68.2% in the HT arm. No overall survival benefit was seen.
CONCLUSION
Adjuvant hyperthermia with a thermal dose more than 10 CEM 43 degrees C T(90) confers a significant local control benefit in patients with superficial tumors receiving radiation therapy.
Related Questions
New comment by Radiation Oncologist at Allegheny Health Network, Pittsburgh ( October 23, 2018)
I usually give 32 Gy/8 fx twice weekly (4 Gy per fraction) though in some cases with limited local disease I will give 40 Gy/10 fx twice weekly (4 Gy per fraction)